Kaponi 2017.

Methods	Aims: to evaluate the effect of inhaled tobramycin and colistin on eradication of P aeruginosa in patients with NCFB [Abstract] Design: randomised trial Total study duration: 3 months Number of study centres and locations: not reported Study setting: not reported Methods of recruitment: not reported Withdrawals: not reported Study start and end dates: not reported Analysis by intent‐to‐treat: not reported
Participants	52 adults were randomised. Inclusion criteria: non‐CF bronchiectasis with > 10⁴ CFUs of P aeruginosa/mL in sputum culture. Exclusion criteria: not reported Mean age: 58.6 years; standard deviation: 15.2 (not reported per group) Gender: 33 women, 19 men (not reported per group) Bronchiectasis diagnosis: not reported Definition of acute exacerbation: not reported. Severity of condition: not reported Baseline lung function: not reported Smoking history: not reported Baseline imbalances: not reported
Interventions	All patients received ciprofloxacin 750 mg bid for 14 days before randomisation. Tobramycin (n = 17) Dose: 300 mg; delivery mode: inhalation using Pari LC Plus jet nebulizer; frequency: twice daily; duration: 3 months Colistin (n = 18) Dose: 1 MU; delivery mode: inhalation using Pari LC Plus jet nebulizer; frequency: twice daily; duration: 3 months Saline solution (n = 17) Dose: 0.9% 4 mL; delivery mode: inhalation using Pari LC Plus jet nebulizer; frequency: twice daily; duration: 3 months
Outcomes	Sputum culture, volume and purulence, dyspnoea (MRC scale), spirometry, and SaO₂ were estimated before and after treatment
Notes	Power calculation: not reported Trial registration: not reported Conflict of interest: not reported Funders: not reported Role of the sponsors: not reported Ethical approval: not reported Conclusions: "Our findings indicate that inhaled antibiotics, tobramycin and colistin may be effective in eradicating P aeruginosa, reducing bacterial load and improving symptoms of bronchiectatic patients. Further investigation is required". Significance values are given for improvements over 3 months, and both antibiotics are described as showing greater improvements compared to saline solution. Direct comparisons between the 2 antibiotics are not reported in this conference abstract.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Selective reporting (reporting bias)	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Other bias	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'